MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology
+$0.05 today
- Market cap
- $80.28M
- Beta
- 0.24
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 2.25M
Average 0.78M
MAIA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
MAIA Biotechnology, Inc.AMEX: MAIA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $6.37M (cash outflow) rose 41.0% year over year, ahead of the +23.1% change in trailing-twelve-month net income. Sequentially, it rose 75.5% from the prior quarter. Over 3 fiscal years it compounded at +12.4% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$16.7M (-25.4%) for the fiscal year ending Dec 2026, a slowdown from the -3.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.37M+75.5% QoQ
- Last fiscal yearDec 2025
- -$22.4M-3.7% YoY
- LTMMar 2026
- -$24.25M+23.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +41.0% | -33.9% | -74.9 pp |
| 1 year | -3.7% | -25.4% | -21.7 pp |
| 3-year CAGR | +12.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (22.4M) USD
- Year-over-year change
- +3.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.4M) | +3.7% |
| FY2024 | 2024-12-31 | (23.25M) | -17.6% |
| FY2023 | 2023-12-31 | (19.77M) | -25.4% |
| FY2022 | 2022-12-31 | (15.77M) | -25.4% |
| FY2021 | 2021-12-31 | (12.58M) | — |
Net Income vs competitors
How MAIA compares with its peers on the latest reported figures
- MAIA's LTM Mar 2026 net income of $24.25M is the 4th largest of the 7 companies compared; the peer median is $25.04M.
- Its year-over-year change of +23.1% is the 3rd highest of 6, against a peer median of +20.8%.
- Over three fiscal years its annual growth of +12.4% compares with a peer median of +4.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $91.72M | +58.4% | — | 345.4% | |
| LTM Mar 2026 | $40.92M | +40.8% | +944.4% | — | |
| LTM Dec 2025 | $34.17M | — | -4.8% | — | |
| LTM Mar 2026 | $24.25M | +23.1% | +12.4% | — | |
| LTM Mar 2026 | $15.91M | -19.9% | +6.3% | — | |
| LTM Mar 2026 | $14.3M | -60.6% | -35.3% | — | |
| LTM Mar 2026 | $12.27M | +20.8% | +4.1% | 824.0% | |
| Peer median (excluding MAIA) | $25.04M | +20.8% | +4.1% | 584.7% | |
Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.58M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.72M | 2.32M | 3.09M | 1.91M | 2.63M |
| Change in Working Capital | 1.13M | 352.78K | 3.09M | (1.24M) | 1.5M |
| Accounts Receivables | 0 | (269.4K) | 158.41K | 56.81K | 80.41K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 805.52K | 211.35K | 471.9K | (118.83K) | 519.72K |
| Other Working Capital | 320.23K | 410.83K | 2.46M | (1.18M) | 899.19K |
| Other Non-Cash Items | 4.61M | 1M | 526.53K | 6.88M | (579.4K) |
| Operating Cash Flow | (4.12M) | (12.1M) | (13.07M) | (15.7M) | (18.84M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 7.43M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.74M | 13.97M | 11.42M | 18.75M | 18.52M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 860.43K | (1.5M) | (2.15M) | (578.1K) | (617.13K) |
| Financing Cash Flow | 14.03M | 12.48M | 9.27M | 18.18M | 17.91M |
| Effect of Forex Changes | 0 | (4.43K) | (117) | (21.55K) | (5.22K) |
| Net Change in Cash | 9.91M | 376.64K | (3.8M) | 2.45M | (943.27K) |
| Free Cash Flow | (4.12M) | (12.1M) | (13.07M) | (15.7M) | (18.84M) |
MAIA Biotechnology, Inc.
AMEX:MAIA
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.